Literature DB >> 21727931

Immunotherapy: Tumor-infiltrating T cells--ready for prime time in melanoma?

Jason Chesney, Kelly M McMasters.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21727931     DOI： 10.1038/nrclinonc.2011.103

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

2.  Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

Authors:  Mark E Dudley; James C Yang; Richard Sherry; Marybeth S Hughes; Richard Royal; Udai Kammula; Paul F Robbins; JianPing Huang; Deborah E Citrin; Susan F Leitman; John Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen Morton; Carolyn Laurencot; Donald E White; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

3.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

4.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.

Authors:  M R Middleton; J J Grob; N Aaronson; G Fierlbeck; W Tilgen; S Seiter; M Gore; S Aamdal; J Cebon; A Coates; B Dreno; M Henz; D Schadendorf; A Kapp; J Weiss; U Fraass; P Statkevich; M Muller; N Thatcher
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

Review 5.  MHC class I antigens and immune surveillance in transformed cells.

Authors:  Natalia Aptsiauri; Teresa Cabrera; Angel Garcia-Lora; Miguel Angel Lopez-Nevot; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Int Rev Cytol       Date:  2007

Review 6.  High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

Authors:  M B Atkins; M T Lotze; J P Dutcher; R I Fisher; G Weiss; K Margolin; J Abrams; M Sznol; D Parkinson; M Hawkins; C Paradise; L Kunkel; S A Rosenberg
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

Review 7.  Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.

Authors:  Nagendra Natarajan; Sucheta Telang; Donald Miller; Jason Chesney
Journal:  Drugs       Date:  2011-07-09       Impact factor: 9.546

8.  Final version of 2009 AJCC melanoma staging and classification.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Michael B Atkins; David R Byrd; Antonio C Buzaid; Alistair J Cochran; Daniel G Coit; Shouluan Ding; Alexander M Eggermont; Keith T Flaherty; Phyllis A Gimotty; John M Kirkwood; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Arthur J Sober; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2009-11-16       Impact factor: 44.544

9.  Transient T cell depletion causes regression of melanoma metastases.

Authors:  Mary Ann Rasku; Amy L Clem; Sucheta Telang; Beverly Taft; Kelly Gettings; Hana Gragg; Daniel Cramer; Sheron C Lear; Kelly M McMasters; Donald M Miller; Jason Chesney
Journal:  J Transl Med       Date:  2008-03-11       Impact factor: 5.531
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.